Dystonia Drugs Market Analysis

  • Report ID: 3473
  • Published Date: Aug 27, 2024
  • Report Format: PDF, PPT

Dystonia Drugs Market Analysis

The market is segmented by treatment into oral therapy, intravenous, surgery and others, out of which, the oral therapy segment is anticipated to hold the largest share in the global dystonia drugs market on account of the fact that most of the medications for dystonia such as Valium, trihexyphenidyl and Klonopin are prescribed via oral mode of dosage, and the non-invasiveness, patient compliance and convenience of this type of drug administration. Moreover, on the basis of end user, the segment for hospitals is predicted to acquire the largest share over the forecast period, which can be credited to the high preference of patients to choose hospital facilities for treatment as a result of patient satisfaction and rising outpatient services. Larger patient admission in hospitals is also evaluated to drive growth to the market segment by the end of the year 2030.     

Our in-depth analysis of the global market includes the following segments:

           Drug Type

  • Torticollis
  • Retrocollis
  • Laterocollis
  • Others

             By Treatment

  • Oral Therapy
  • Intravenous
  • Surgery
  • Others

 

 

           By End User

  • Hospitals
  • Clinics
  • Others
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3473
  • Published Date: Aug 27, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of dystonia drugs is assessed at USD 909.87 million.

Dystonia Drugs Market size was over USD 872.19 million in 2023 and is anticipated to reach USD 1.72 billion by 2036, growing at around 5.4% CAGR during the forecast period i.e., between 2024-2036. The market growth is driven by growing prevalence of dystonia disorders and increasing number of incidences of musculoskeletal disorders.

Asia Pacific is expected to dominate majority revenue share by 2036, on the back of increase in the geriatric population, large patient pool, and rapid growth of pharmaceutical sector in countries such as China, Japan and India.

The major players in the market are Pfizer, Inc., Ipsen Biopharmaceuticals, Inc., Revance Therapeutics, Inc., Solstice Neurosciences LLC, US Worldmeds, LLC, and others.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample